Please assess the completion status of the following clinical trial:

Trial Title: The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Must have type 2 diabetes.~* Must be at least 30 and less than 80 years of age at the time of Visit 1.~* Must be on at least two oral antidiabetes medications for at least 90 days.~* Must have an HbA1c 1.2 to 2.0 times the upper limit of normal reference range at the local lab.~Exclusion Criteria:~* Must not have used insulin on a regular basis in the last 12 months.~* Must not have had more than one episode of severe hypoglycemia in the last 24 weeks.~* Must not have a body mass index (BMI) of greater than 45 (morbid obesity).~* Must not have clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease.~* Must not be pregnant or intend to get pregnant during course of the study.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (Type: ACTIVE_COMPARATOR): Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.
- Lispro Low Mix (Type: EXPERIMENTAL): Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.
- Lispro Mid Mix prior Lispro Low Mix addendum (Type: EXPERIMENTAL): Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.
- Lispro Low Mix prior Glargine addendum (Type: EXPERIMENTAL): Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase
- Basal bolus prior Lispro Low Mix addendum (Type: ACTIVE_COMPARATOR): Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
- Basal bolus prior Glargine addendum (Type: ACTIVE_COMPARATOR): Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).